English courts may set the terms for global FRAND licences to portfolios of declared standard essential patents.

Joint Managing Partner Liz Cohen was interviewed by the Patent Lawyer Magazine, in their Women in IP Leadership segment, launched in their December 2020 issue.

The relative contribution of a joint author is a factually complicated and difficult matter to assess.

The Department of Health & Social Care (DHSC) has commenced a public consultation on mandatory disclosure of payments by life sciences companies to the healthcare sector.

The introduction of the Bill gives rise to the first mandatory notification regime in the UK for transactions in key sectors.

It is important for the Courts to find the right balance between patentees' rights and the public interest when deciding whether to grant an injunction.

On 17 December 2020, the Chancellor announced that the Coronavirus Job Retention Scheme ("CJRS") would be extended until the end of April 2021.

This was an appeal by both parties following the Opposition Division’s interlocutory decision to maintain the patent in issue in an amended form.

On 26 April 2007 the ECJ handed down its latest judgement in relation to the long running dispute between various pharmaceutical producers, including GlaxoSmithKline and Boehringer Ingelheim KG and a number of parallel importers.

Philip Ball writes on an important contribution to discussion on the twilit zone between human embryo models and actual human embryos.

Two judgments handed down in the last year have caused renewed interest in the court's ability to 'pierce the veil of incorporation'.

The use of Customs controls to intercept counterfeit and pirated goods is fairly well-known and widely used. However, many patentees may not be aware that goods suspected of infringing a patent or supplementary protection certificate (SPC) may be detained by Customs authorities on entry into the EU.

Employee compensation for inventions has been in the headlines this year. In particular, two decisions in Japan in January sent shock waves through industry in that country, with the inventor of the blue LED being awarded a staggering 20 billion yen (over £100 million). At the same time the employee compensation provisions of the UK Patents Act will be amended shortly (probably with effect from 1 January 2005) to make compensation easier to obtain here.

There are four procedures for applying for a marketing authorisation for a medicinal product. These are a national procedure, a centralised procedure, the mutual recognition procedure and the decentralised procedure.

A little over a year since the Commission sketched out its potential policy options for AI legislation in a White Paper on AI, and the fruition of an extensive panoply of workshops, forums, ..

While the title suggests some inherent conflict between ‘privacy rights’ and ‘intellectual property rights’, this isn’t necessarily the case. In most situations, privacy rights and IP rights don’t compete with each other. This is because privacy rights are focussing on protecting the private life of individuals (broadly speaking), while IP rights are often focussing on the protection of publicly distributed materials and information (the law of confidentiality, perhaps being a slight exception

The Disability Discrimination Act 1995 (‘the DDA’) brought in measures to prevent discrimination against disabled people. Since 1 October 1999 service providers have had to make "reasonable adjustments" for disabled people, such as providing additional help or making changes to the way they provide their services. On 1 October 2004, Part III of the DDA came fully into force. This extends the obligation to require changes to the physical features of premises in order to overcome physica

With recent decisions from the UK’s highest court and both recent and pending legislative changes, the next year will be an interesting one for patent litigation in the UK. Zoë Butler and Liam Curren of Bristows explain some of the main developments, and also highlight why the UK is a fast and cost-effective forum for patent litigation.

The restrictions imposed by Article 25 of the Data Protection Directive (95/46/EC) on organisations transferring personal data out of the European Economic Area aren’t new. Indeed, few, if any, data protection issues have attracted as much attention as those presented by Article 25. Its provisions needn’t be set out again here; suffice to say, nearly ten years after its restrictions first appeared, transferring personal data out of the EEA is not a straightforward matter; far from it.

The AI Act continues to contain a concerning flaw as regards the testing of any high risk AI System that also qualifies as a medical device under the Medical Devices Regulation...